A Study of TTYP01 in Healthy Adult Subjects

NCT ID: NCT04370431

Last Updated: 2025-01-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-24
• Study Completion Date: 2021-01-08

Brief Summary

This is integrated Phase 1, Single centre, Randomized study will be conducted in 3 parts, each with a specific primary objective:

Part A: To characterise the safety and tolerability of TTYP01 in healthy adult subjects; Part B: To evaluate the bioavailability of TTYP01 tablets in healthy adult subjects; Part C: To characterise the food effect of TTYP01 tablets in healthy adult subjects under the fasted or fed condition.

The secondary objectives of the study are to evaluate the pharmacokinetic (PK) profiles of TTYP01 tablets in healthy adult subjects, and the effects of gender on the PK of TTYP01 tablets in healthy adults. In Part A of the study, a total of 32 healthy adult subjects will be enrolled over four consecutive cohorts (8 per cohort), with participants receiving a single dose of TTYP01 at one of four levels (60, 120, 10 or 240 mg), to assess the PK and safety of TTYP01. In Part B, 16 healthy adults will be randomized into 2 groups, and the comparison of the PK of edaravone (TTYP01 and intravenous (IV) edaravone) will be evaluated using a randomized, open-label, four-period crossover design under fasted conditions. In the first crossover period, subjects will receive a single fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase, and in the second crossover period, subjects will receive a higher fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase. In Part C, 18 healthy subjects will be enrolled to evaluate the effect of food on the PK of TTYP01 using a randomized, open-label, two-period cross-over design. Participants will be randomized into two groups and administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fed conditions and the second dosing day (Period 2) under the fasted conditions, while the other group being administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fasted conditions and the second dosing day (Period 2) under the fed conditions.

Conditions

Healthy Adult Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

PartA: TTYP01 single ascending doses

In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.

Group Type: EXPERIMENTAL

TTYP01 single ascending doses

Intervention Type: DRUG

TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)

Part A: Placebo

Placebo control for Part A of the study

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo control for Part A of the study

Part B: TTYP01 (oral edaravone) first then IV edaravone

Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.

Group Type: EXPERIMENTAL

TTYP01, 60 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet)

TTYP01, 120 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet)

Radicut® (ampoule), 30 mg

Intervention Type: DRUG

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

Radicut® (bag) , 60 mg

Intervention Type: DRUG

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

Part B: IV edaravone first then TTYP01 (oral edaravone)

Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.

Group Type: EXPERIMENTAL

TTYP01, 60 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet)

TTYP01, 120 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet)

Radicut® (ampoule), 30 mg

Intervention Type: DRUG

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

Radicut® (bag) , 60 mg

Intervention Type: DRUG

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

Part C: TTYP01: fasted dosing first then fed dosing

Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.

Group Type: EXPERIMENTAL

TTYP01, up to 120 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

Part C: TTYP01: fed dosing first then fasted dosing

Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.

Group Type: EXPERIMENTAL

TTYP01, up to 120 mg

Intervention Type: DRUG

TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

Interventions

TTYP01 single ascending doses

TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)

Intervention Type: DRUG

Placebo

Placebo control for Part A of the study

Intervention Type: DRUG

TTYP01, 60 mg

TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention Type: DRUG

TTYP01, 120 mg

TTYP01 oral tablets (30 mg edaravone per tablet)

Intervention Type: DRUG

Radicut® (ampoule), 30 mg

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

Intervention Type: DRUG

Radicut® (bag) , 60 mg

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

Intervention Type: DRUG

TTYP01, up to 120 mg

TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

Intervention Type: DRUG

Other Intervention Names

edaravone tablet; Edaravone tablet; Edaravone tablet; Edaravone injection; Edaravone injection; Edaravone tablet

Eligibility Criteria

Inclusion Criteria

• Age between 18 and 40, inclusive;
• Non-smokers, ex-smokers and moderate smokers will be included. "A moderate smoker is defined as someone smoking 5 cigarettes or less per day, an ex-smoker is someone who completely stopped smoking for at least 3 months.";
• If female, must be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception (e.g., oral, intrauterine device [IUD; diaphragm], injectable, transdermal or implantable contraception) or abstinence, for at least 1 month prior to randomization, during the study and 3 month following completion of the study. Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at screening;
• Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive; and a total body weight >50 kg at screening for male subjects, total body weight > 45 kg for female subjects;
• Female subjects of child bearing potential and all male participants who have not had a vasectomy must use effective contraception during the study
• Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures), and evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study;
• Willingness and ability to comply with study procedures and follow-up examination.
• Adequate organ function as evidenced by the following peripheral blood counts or serum chemistry values within 28 days before randomization:

1. Hemoglobin greater than or equal to 9 g/dL

2. Neutrophil count (ANC) greater than or equal to 1,500/microL

3. Platelet count greater than or equal to 100,000/microL

4. Serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 132.6 micromol/L) and creatinine clearance greater than or equal to 60 ml/min

5. Creatine phosphokinase (CPK) less than or equal to 2x upper limit of normal (ULN)

6. Hepatic function variables:

1. Total bilirubin ≤ 1.5x ULN

2. Total alkaline phosphatase (ALP) ≤ 1.5x ULN, or if > 1.5x ULN, then ALP liver fraction or 5' nucleotidase must be ≤1x ULN

3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be ≤ 2.5x ULN

Exclusion Criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
• Subjects with a history of hypersensitivity to edaravone or any of the inactive ingredients of the formulation (such as sulfite and sodium bisulfite).
• Subjects with PR >240 msec, QRS =120 msec, or QTcF >450 msec for male & QTcF >470 msec for female on the screening or Day -1 ECG, or any clinically significant electrocardiographic abnormality in the opinion of the investigator.
• Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product.
• Female subjects currently pregnant or lactating; female subjects able to bear children or of child bearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product.
• Subjects whose urine drug/alcohol screening was positive at the time of screening and/or on Day-1.
• Subjects having difficulty in swallowing pills/tablets.
• Subjects smoking > 5 cigarettes per day within 3 months prior to the screening visit.
• Subjects unwilling or unable to comply with the Lifestyle Guidelines described in the protocol.
• Subjects who are investigational site staff members directly involved in the conduct of the studies and their family members, site staff members otherwise supervised by the Investigator, or subjects who are the sponsors' employees directly involved in the conduct of the studies.
• Evidence of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
• Subjects who have participated in another clinical trial less than 3 months before or donated his/her blood in a quantity greater than 200 milliliters (mL) within 1 month of the screening period of this clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

TIGERMED AUSTRALIA PTY LIMITED

UNKNOWN

Sponsor Role: collaborator

CMAX Clinical Research Pty Ltd

UNKNOWN

Sponsor Role: collaborator

Shanghai Auzone Biological Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sepehr Shakib, MD

Role: PRINCIPAL_INVESTIGATOR

Royal Adelaide Hospital

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Countries

Australia

Other Identifiers

Auzone-01

Identifier Type: -

Identifier Source: org_study_id